These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 20833716)
1. Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes. Iwabu Y; Kinomoto M; Tatsumi M; Fujita H; Shimura M; Tanaka Y; Ishizaka Y; Nolan D; Mallal S; Sata T; Tokunaga K J Biol Chem; 2010 Nov; 285(46):35350-8. PubMed ID: 20833716 [TBL] [Abstract][Full Text] [Related]
2. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. Binka M; Ooms M; Steward M; Simon V J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041 [TBL] [Abstract][Full Text] [Related]
4. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity. Dang Y; Wang X; York IA; Zheng YH J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083 [TBL] [Abstract][Full Text] [Related]
5. Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Yamashita T; Kamada K; Hatcho K; Adachi A; Nomaguchi M Microbes Infect; 2008; 10(10-11):1142-9. PubMed ID: 18603011 [TBL] [Abstract][Full Text] [Related]
6. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity. Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180 [TBL] [Abstract][Full Text] [Related]
7. Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity. Vetter ML; Johnson ME; Antons AK; Unutmaz D; D'Aquila RT PLoS Pathog; 2009 Feb; 5(2):e1000292. PubMed ID: 19197360 [TBL] [Abstract][Full Text] [Related]
8. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. Refsland EW; Hultquist JF; Harris RS PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680 [TBL] [Abstract][Full Text] [Related]
9. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers. Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111 [TBL] [Abstract][Full Text] [Related]
10. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. He Z; Zhang W; Chen G; Xu R; Yu XF J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467 [TBL] [Abstract][Full Text] [Related]
11. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G. Feng Y; Love RP; Chelico L J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055 [TBL] [Abstract][Full Text] [Related]
12. Genetic and functional characterization of HIV-1 Vif on APOBEC3G degradation: First report of emergence of B/C recombinants from North India. Ronsard L; Raja R; Panwar V; Saini S; Mohankumar K; Sridharan S; Padmapriya R; Chaudhuri S; Ramachandran VG; Banerjea AC Sci Rep; 2015 Oct; 5():15438. PubMed ID: 26494109 [TBL] [Abstract][Full Text] [Related]
13. Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F. Albin JS; Anderson JS; Johnson JR; Harjes E; Matsuo H; Krogan NJ; Harris RS J Mol Biol; 2013 Apr; 425(7):1172-82. PubMed ID: 23318957 [TBL] [Abstract][Full Text] [Related]
14. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein. Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652 [TBL] [Abstract][Full Text] [Related]
15. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068 [TBL] [Abstract][Full Text] [Related]
16. [HIV Restriction Factor APOBEC3G and Prospects for Its Use in Gene Therapy for HIV]. Tikhonov AS; Mintaev RR; Glazkova DV; Bogoslovskaya EV; Shipulin GA Mol Biol (Mosk); 2022; 56(4):546-556. PubMed ID: 35964311 [TBL] [Abstract][Full Text] [Related]
17. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication. Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381 [TBL] [Abstract][Full Text] [Related]
19. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Donahue JP; Vetter ML; Mukhtar NA; D'Aquila RT Virology; 2008 Jul; 377(1):49-53. PubMed ID: 18499212 [TBL] [Abstract][Full Text] [Related]
20. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]